Improving Immunotherapy for Oral Cancer
Reprogramming the Tumor-Immune Interface in Oral Cancer
['FUNDING_OTHER'] · STANFORD UNIVERSITY · NIH-11113817
This project looks for new ways to help your body's immune system fight oral cancer more effectively.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11113817 on ClinicalTrials.gov |
What this research studies
Oral squamous cell carcinoma (OSCC) is a serious cancer with a low survival rate, and current immune treatments only help some patients. This project explores how tumor cells interact with the immune system to understand why some treatments work better than others. We are using patient tumor samples and special models to learn how to make the immune system stronger against human OSCC. Our goal is to discover how to make tumors more visible to the immune system and improve the function of immune cells that kill cancer. This foundational work aims to overcome challenges in current immunotherapy approaches.
Who could benefit from this research
Good fit: Patients with oral squamous cell carcinoma who are not responding well to current immunotherapies or are seeking new treatment options might eventually benefit from this research.
Not a fit: Patients without oral squamous cell carcinoma or those whose cancer is not related to immune system interactions may not directly benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to more effective immunotherapy treatments for oral squamous cell carcinoma, improving patient outcomes.
How similar studies have performed: Immunotherapy has shown promising results in some cancers, but this specific approach to reprogramming the tumor-immune interface in oral cancer is still under intense investigation.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUNWOO, JOHN B — STANFORD UNIVERSITY
- Study coordinator: SUNWOO, JOHN B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers